Inhibition of aromatase is an efficient approach for the prevention and treatment of breast cancer. New A,D-ring modified steroid analogues of formestane and testolactone were designed and synthesized and their biochemical activity was investigated in vitro in an attempt to find new aromatase inhibitors and to gain insight into their structure-activity relationships (SAR). All compounds tested were less active than formestane. However, the 3-deoxy steroidal olefin 3a and its epoxide derivative 4a proved to be strong competitive aromatase inhibitors (K i ) 50 and 38 nM and IC 50 ) 225 and 145 nM, respectively). According to our findings, the C-3 carbonyl group is not essential for anti-aromatase activity, but 5R-stereochemistry and some planarity in the steroidal framework is required. Furthermore, modification of the steroidal cyclopentanone D-ring, by construction of a δ-lactone six-membered ring, decreases the inhibitory potency. From the results obtained, it may be concluded that the binding pocket of the active site of aromatase requires planarity in the region of the steroid A,B-rings and the D-ring structure is critical for the binding.
Introduction
Estrogens are required for normal tissue growth and development, but they are also responsible for the promotion of certain tumors, such as prostatic hyperplasia, prostate, endometrial, and especially breast cancers. 1 In fact, 30-50% of breast cancers are considered to be estrogen-dependent, 2, 3 and regression can be achieved by reducing blood and tissue estrogen levels. The highest incidence of breast cancer occurs in postmenopausal women, 4 whose ovarian function and hypophyseal control of estrogen production has ceased. In these women, estrogen biosynthesis occurs mostly in peripheral tissues such as liver, skin, muscle, and adipose tissue. [5] [6] [7] For this reason, total blockage of estrogen biosynthesis is easier to achieve by chemical means rather than by surgical therapy. 8 Two main chemical approaches have been successfully applied as endocrine therapy of estrogen-dependent breast cancer. One is directed to the estrogen receptor by use of selective estrogen receptor modulators (SERMs), among which tamoxifen is the most popular one. The other is directed to aromatase, the key enzyme responsible for estrogen biosynthesis. 9, 10 Since estrogens are formed in the last step of the biosynthetic sequence of steroid production, aromatase inhibition provides a basis for the development of selective chemotherapies for treatment and prevention of estrogen-sensitive breast cancers. 11 Furthermore, the therapeutic potential of aromatase inhibitors stretches beyond postmenopausal women with breast cancer, because these inhibitors have also been shown to be clinically relevant in the management of other estrogen-dependent pathological processes such as endometriosis, 12 gynecomastia, prostatic hyperplasia, and prostate cancer. 13 For these reasons, several steroidal aromatase inhibitors, based on the structure of the natural substrate androstenedione, have been designed and synthesized in several laboratories. Exemestane and the well-established formestane ( Figure 1 ) are two examples of these kinds of compounds that are known to be very efficient in the treatment of patients in whom other anti-estrogen therapies failed. 8, 14 In the present study our focus is on the design, synthesis, and biochemical evaluation of a new series of substituted steroids containing modifications in the A-and D-rings. The new compounds were obtained by chemical modifications to the structure of the natural enzyme substrate, androstenedione, to achieve new aromatase inhibitors in order to further study the structure-activity relationships (SAR). The studied SAR were correlated with three main features, namely, the A-ring substitution pattern and the planarity of this ring, the C-5 stereochemistry in the A/B-ring fusion, and the D-ring structure. Numazawa and co-workers [15] [16] [17] [18] have performed several SAR studies in steroid aromatase inhibitors indicating the existence of a binding pocket in the active site of the enzyme, which can accommodate several chemical groups placed at the C-4 position of the steroids. According to this information, we embarked on the design, synthesis, and biochemical evaluation of some C-4 oxo-(2), C-4 keto-(6 and 10), C-4 hydroxy-(5a, 5b, and 8), and C-4 hydroxycyano-(11) substituted androstanes (Schemes 1 and 2). In the same way, the C-3 carbonyl group of the substrate androstenedione has been thought to be important to the binding of aromatase and is also present in many inhibitors. However, some recent studies have shown that this group could be removed if some planarity were maintained in the steroid A-ring. 16, 18 For this reason, we prepared the 3-deoxy steroids 3a, 4a, and 4b (Schemes 1 and 2) having olefin and epoxy groups, that confer the desired planarity to the A-ring, and evaluated their inhibitory activity. We were also interested in studying the effect of the C-5 stereochemistry of the A/Bring fusion on drug-receptor interaction, so the 5R/ -epimers 4a/4b and 5a/5b were prepared and evaluated. With respect to the steroid D-ring, there are not many modifications reported in the literature. However, some δ-lactone D-ring steroids such as testolactone, the first steroidal aromatase inhibitor clinically used for breast cancer treatment (Figure 1) , 19 have also shown antiScheme 1. Synthesis of Aromatase Inhibitors from androstenedione 1 a aromatase activity. On the basis of these, we decided to prepare and evaluate the δ-lactone D-ring steroids 8, 9, 10, and 11 (Scheme 2). Furthermore, successful efforts have been made to combine in the same structure the diosphenol A-ring of formestane and the δ-lactone D-ring of testolactone, as observed in compound 9.
Results
Chemistry. All steroids were prepared from androstenedione 1 by the routes depicted in Schemes 1 and 2. The A-ring lactone aldehyde 2 was first obtained as a byproduct in a synthetic route for aromatase inhibitors previously developed in our laboratory. It was formed through a rearrangement, which occurred after controlled oxidation of 1 in methanol with alkaline potassium permanganate (Tavares da Silva, unpublished results). Clemmenson-type reduction of 1 with zinc dust in acetic acid solution afforded the isomeric mixture (2.3: 1, by NMR) of the 5R-and 5 -olefins 3a and 3b in almost quantitative yield. Separation of the pure 3a (60%) from the mixture was achieved by n-hexane crystallization. 20 Treatment of 5R-androst-3-en-17-one 3a (Scheme 2) with performic acid generated in situ led, after workup, to the trans-diaxial diol, 3R,4 -dihydroxy-5R-androstan-17-one 5a, in 96% yield. The 3R,4R-epoxide 4a was also obtained from the reaction of 3a with performic acid but with methylene chloride as reaction solvent instead. In this case, due to the low solubility of the resulting formic acid in this solvent, further cleavage of the epoxide intermediate was prevented and 4a was the only product formed, also in near quantitative yield. Epoxide 4b was prepared as described for 4a but with a 1:3 mixture of 3a and 3b as starting material. The abovementioned mixture has been used as we could not isolate the pure 3b from it. Under these conditions a 1:3 mixture of epoxides 4a and 4b was obtained, from which 4b was easily isolated by crystallization. Treatment of 4b with 90% formic acid solution afforded a mixture of two other diols and of the desired 3,4-transdiaxial diol 5b, which was isolated by crystallization or column chromatography in 48% yield. 20 Swern-type oxidation of 5a with dimethyl sulfoxide, activated with trifluoroacetic anhydride, gave quantitatively kinetic diosphenol, the 3-hydroxy-5R-androst-2-ene-4,17-dione, 21 which by acid-or base-catalyzed isomerization with HCl/CH 3 COOH or NaOMe/MeOH led to the desired thermodynamic diosphenol 4-OHA 7 as the only product, formed in 80% yield. The same Swern-type oxidation applied to 5 -diol 5b afforded a mixture with a variable composition (1:2 to 2:1, by NMR) of a 5 -kinetic diosphenol, the 3-hydroxy-5 -androst-2-ene-4,17-dione, 20 and an unstable triketone, the 5 -androstane-3,4,17-trione, 20 which after acid-or base-catalyzed isomerization were also converted in similar yield to diosphenol 7. Treatment of diol 5a in methylene chloride with oxone catalyzed with alumina in the heterogeneous phase allowed the selective oxidation of the C-4 hydroxyl group, affording the R-ketol 6. Baeyer-Villiger oxidation of the 17-keto group of 5a with monoperoxyphthalic acid magnesium salt hexahydrate (MMPP) yielded the dihydroxylactone derivative 8 in 90-94% yield. Further oxidation of 8 with dimethyl sulfoxide activated with trifluoroacetic anhydride gave a kinetic diosphenol, the 3-hydroxy-D-homo-17a-oxa-5R-androsta-2-ene-4,17-dione, 22 which after acid-catalyzed isomerization yielded quantitatively the thermodynamic diosphenol 9. Oxidation of 8 in heterogeneous phase with the oxone alumina system (also used previously for the diol 5a) gave the R-ketol 10. Treatment of 10 with acetone cyanohydrin and triethylamine provided the lactone cyanohydrin derivative 11.
Biochemical Properties. Inhibition of aromatase activity by the newly prepared A-and D-ring modified steroids was evaluated in human placental microsomes by a radiometric assay in which tritiated water, released from [1 -3 H]androstenedione into the incubation medium, was used as an index of estrogen formation. 23 The results of these studies are shown as percentage of inhibition for all compounds at 2 µM, relative to an assay in the absence of an inhibitor ( Table 1) . The wellknown aromatase inhibitor 4-hydroxyandrostenedione ( Figure 1) , with an inhibitory capacity of 99.1% ( 0.04%, was used as reference. For the inhibitors showing antiaromatase activity equal to or higher than 70% (3a, 4a, 6, and 9), IC 50 was determined in saturating concentrations (200 nM) of androstenedione. In addition, the type of binding to the active site of aromatase was characterized and the apparent inhibition constant (K i ) was determined by use of different inhibitor and substrate concentrations. The inhibition kinetic studies were performed with human placental microsomes and the results were plotted as Lineweaver-Burk plots. The inhibition type of all compounds tested was competitive. A representative Lineweaver-Burk plot of aromatase inhibition is shown in Figure 2 for compound 9. The apparent inhibition constants (K i ), which characterize the enzyme affinity, were obtained by Dixon plots (Figure 3 ). The IC 50 value for formestane was evaluated in our test system and used for comparison. This compound presented higher inhibitory activity than all the synthesized compounds. The IC 50 , K i , type of inhibition and K m /K i ratios for the more active inhibitors are shown in Table 2 . In these studies, the apparent K m and V max values for aromatase with androstenedione as substrate were 57.5 nM and 48 pmol min -1 (µg of protein) -1 , respectively.
Discussion
Compound 3a, the 5R-epimer of the 3,4-olefin, showed 95.9% ( 0.6% rate of inhibition. It is a strong inhibitor of aromatase with an IC 50 ) 225 nM and has higher affinity for the enzyme than its natural substrate androstenedione (K i ) 50 nM versus K m ) 57.5 nM, respectively). Compound 4a, the 5R-epimer of the 3,4-epoxide, showed 96.4% ( 0.1% inhibition of aromatase, revealing it to be the best competitive inhibitor among all the compounds studied in this work. This epoxide 4a presented an IC 50 ) 145 nM and was found to bind the enzyme with an affinity 1.5 times higher (K i ) 38 nM) than that of the natural substrate (57.5 nM). Numazawa et al. 16 have already reported that 3-deoxy-4-ene and 3-deoxy-5-ene derivatives of androstenedione are competitive inhibitors of aromatase. In this work we pointed out that, in addition to these derivatives, the 3-deoxy-3-ene derivative 3a of androstenedione is also a strong competitive inhibitor of aromatase. Furthermore, the 3,4-epoxide derivative 4a, which has the same stereochemistry requirements in the A-ring, is also a strong competitive aromatase inhibitor. These results stress the importance of A-ring planarity in the interaction with the active site of the enzyme. The lack of a C-3 carbonyl group in these compounds also indicates that this feature is not a determinant for inhibition, as previously observed by Numazawa. 16, 24 Compound 5a, the 5R-epimer of a 3,4-diol, showed an inhibition of 34.6% ( 1.0%, and its 4-keto derivative, the R-ketol 6, showed a significant increase in the inhibitory capacity of 83.3% ( 1.3%. These results demonstrate, once more, the importance of the planarity in the A-ring for the inhibition, now conferred by a C-4 carbonyl group in 6. Compound 2, a 4-oxa steroid with a 5R-aldehyde group showed only 11.0% ( 1.9% inhibition. In this way, more studies should be performed in order to understand the influence of 4-oxa and 5R-aldehyde groups in the antiaromatase activity.
The effect of the C-5 stereochemistry on the inhibition of aromatase was studied for the 5R/ -epimers 4a/4b and 5a/5b. Within the 3,4-epoxide derivatives 4a and 4b, the 5R-substituted steroid 4a showed 96.4% aromatase inhibition in contrast to the corresponding 5 -epimer 4b, which had a dramatic reduction in inhibition (14.6% ( 1.6%). Within compounds 5a and 5b, the 5R-epimer of the 3,4-diol 5a inhibited aromatase 34.6%, whereas the correspondent 5 -epimer 5b showed a decrease in the inhibitory activity (10.1% ( 1.8%). These results indicate that the angle formed in the A/B-ring junction is crucial in order to better fit the enzymatic active site. The 5 -epimers, in which A-and B-rings are almost perpendicular, will not be well accommodated by the enzyme.
The effect of the D-ring modification in the inhibition of aromatase was observed in steroids 8, 9, and 10, in which six-membered δ-lactone rings were introduced. Compound 9, combining the diosphenol A-ring of the potent inhibitor formestane and the δ-lactone D-ring of testolactone (Figure 1) , showed 72.5% aromatase inhibition and an IC 50 ) 1.85 µM, compared to 99.1% ( 0.04% and IC 50 ) 0.042 µM for formestane. Similar reduction in the inhibitory capacity was observed for the pair of compounds 6 and 10, which showed inhibitory activities of 83.3% ( 1.3% and 16.6% ( 1.5%, respectively. Compound 6 was a competitive inhibitor of aromatase, with IC 50 ) 670 nM. It blocks the enzyme activity to a much greater extent than the corresponding D-ring lactone compound 10 (IC 50 > 100 µM). In the same way, compound 5a showed an inhibitory activity of 34.6% ( 1.0%, while the introduction of the δ-lactone ring, yielding derivative 8, strongly affects inhibition (8.1% ( 1.8%). These results suggest that the inhibitory activity of testolactone is probably not due to its δ-lactone D-ring. Compound 11, the 4-cyano derivative of 8, showed a slight increase in the inhibitory activity (17.6% ( 1.6%) compared to its precursor. The chemically reactive cyano group in the C-4 position of this compound is also present in the most recent third generation cyano azole-type aromatase inhibitors, 25 revealing it to be an important feature for enzyme inhibition. This result also indicates that the C-4 position is a critical region for the interaction of steroids with aromatase. 
Conclusions
Our data showed that modification in the A-and D-rings of androstenedione provides potent, easily available, and structurally simple aromatase inhibitors. Nevertheless, none of the compounds prepared was shown to be a stronger inhibitor than formestane. Only specific changes were allowed in the A-ring of steroids in order to obtain potent inhibitors. The C-3 carbonyl is not a determinant group for the interaction of the studied steroids with the enzyme and for its inhibition. In fact, the 3-deoxy compounds 3a and 4a were demonstrated to be strong competitive inhibitors of aromatase. They have also shown higher affinity toward the enzyme than its natural substrate androstenedione. These results suggest that a 3,4-double bond or a 3,4-epoxide group will confer the A-ring planarity required for anti-aromatase activity, according to the previous observations by Numazawa and co-workers. [15] [16] [17] [18] 24 Epoxide 4a proved to be the most potent inhibitor, revealing that, in addition to planarity, the oxygen atom near the C-4 region will be important for activity. A C-4 carbonyl group, as observed in 6, may also contribute to the above-mentioned requirements for anti-aromatase activity. In addition to planarity in the A-ring, planarity in the A/B-ring junction of the steroids seems also to be important for enzyme inhibition. Our results therefore stress that the 5R-stereochemistry is required for inhibition. Concerning the D-ring, the replacement of the original steroid cyclopentanone ring by a six-membered δ-lactone ring reduces the inhibitory activity. The magnitude of this reduction seems to be also dependent on the substitution pattern in the A-ring, as observed for compounds 8, 9, and 10. This modification in the D-ring may induce structural alterations in the steroidal framework, affecting their ability to bind to the active site of the enzyme.
The preliminary biological profile indicates that it is important to synthesize new steroid derivatives in order to refine the encountered SAR for the prepared compounds.
Experimental Section
Chemistry: 3,17-Dioxo-4-oxaandrostane-5r-carbaldehyde (2). To a cold (-5°C) stirred solution of androst-4-ene-3,17-dione 1 (3.0 g, 10.5 mmol) in 200 mL of methanol, a 2.5% solution of potassium permanganate in aqueous KOH, 0.05 N (130 mL, 20.6 mmol), was added dropwise. The temperature was then raised to 15°C and after 5-10 min the excess oxidant was destroyed with saturated aqueous Na 2S2O5 (20 mL). After separation of the formed MnO2 by centrifugation, the methanol was evaporated and the solution diluted with water (200 mL), neutralized with aqueous 1 N H2SO4, and extracted with CH2-Cl2 (3 × 100 mL). The organic extract was washed with 10% aqueous Na2S2O5 (100 mL) and then water (2 × 100 mL), dried (MgSO4), and evaporated to dryness to give 1.36 g (41%) of a crude product from where the title compound 2 was isolated by crystallization from absolute ethanol.
5r-and 5 -Androst-3-en-17-one (3a and 3b). The title olefins 3a and 3b were prepared from androst-4-ene-3,17-dione 1 (500 mg, 1.75 mmol) through a Clemmenson-type reduction with zinc dust in acetic acid, according to the reaction conditions previously described. 20 The crude product obtained as a white crystalline solid (476 mg) was composed of an isomeric mixture (2.3:1 by NMR) of 5R-olefin 3a and 5 -olefin 3b. Crystallization of the mixture from n-hexane gave the pure 3a (285 mg, 60%). The 5 -epimer 3b could not be isolated and has been identified in the mixture with the 5R-epimer only by 3r,4r-Epoxy-5r-androstan-17-one (4a) . The title compound 4a was prepared from oxidation of olefin 3a (67.5 mg, 0.25 mmol) in methylene chloride with performic acid generated in situ with 30% hydrogen peroxide (0.05 mL, 0.5 mmol) and 90% formic acid (0.05 mL, 1.18 mmol), according to the reaction conditions previously described. 20 Epoxide 4a (75 mg, 96%) was obtained as the only isolated product identified.
3 ,4 -Epoxy-5 -androstan-17-one (4b). The title epoxide 4b was prepared as described above for 4a but with a mixture of olefins 3a and 3b (1:3 by NMR) as the starting material. Under these conditions, a 1:3 mixture of 4a and 4b was obtained, from which 4b was isolated by slow diethyl ether crystallization.
3r,4 -Dihydroxy-5r-androstan-17-one (5a). The title 5R-vic-diol 5a (75 mg, 96%) was prepared from olefin 3a (67.5 mg, 0.25 mmol) by oxidation with the in situ generated performic acid and isolated according to the reaction conditions previously described. 21 3 ,4r-Dihydroxy-5 -androstan-17-one (5b). The title 5 -vic-diol 5b was obtained in a mixture with two other diols, by cleavage of epoxide 4b (200 mg, 0.69 mmol) with formic acid and was separated (102 mg, 48%) by column chromatography, according to the reaction conditions previously described. 20 3r-Hydroxy-5r-androstane-4,17-dione (6). To a solution of 3R,4 -dihydroxy-5R-androstan-17-one 5a (50 mg, 0.16 mmol) in methylene chloride with some drops of methanol (1.7 mL) were added wet alumina (335 mg) and oxone (252 mg, 0.41 mmol). The suspension was sonicated under inert atmosphere in a cleaning bath ("Bandelin", 450 W, 35 kHz) at 22°C until the steroid was consumed [30 min, thin-layer chromatogtaphy (TLC)]. After dilution with methylene chloride, the suspension was filtered, washed with aqueous HCO 3Na and water, dried over magnesium sulfate, and evaporated to dryness to give a crude extract (43 mg, 87%) from which the title compound was isolated by crystallization.
4-Hydroxyandrost-4-ene-3,17-dione (7): (i) Oxidation of Diols 3r,4 -Dihydroxy-5r-androstan-17-one (5a) and 3 ,4r-Dihydroxy-5 -androstan-17-one (5b). Swern-type oxidation of the 5R-vic-diol 5a (203 mg, 0.66 mmol) with dimethyl sulfoxide (DMSO; 0.15 mL, 2.11 mmol) and trifluoroacetic anhydride (0.27 mL, 1.91 mmol), according to the reaction conditions previously described, 20 yielded a crude 5R-kinetic diosphenol, the 3-hydroxy-5R-androst-2-ene-4,17-dione (199 mg, 98%), which was purified by column chromatography.
The same oxidative conditions used for the 5R-vic-diol 5a were applied to the 5 -vic-diol 5b, giving a mixture with a variable composition (1:2 to 2:1 by NMR) of a 5 -triketone, the 5 -androstane-3,4,17-trione, and a 5 -kinetic diosphenol, the 3-hydroxy-5 -androst-2-ene-4,17-dione. 20 The unstable above-mentioned 5 -kinetic diosphenol and the triketone could not be separated because of their rapid conversion into diosphenol 7.
(ii) Isomerization of the Kinetic 5r-and 5 -Diosphenols and 5 -Triketone. The title diosphenol 7 was prepared in a convergent manner by isomerization of the 5R-and 5 -kinetic diosphenols and 5 -triketone, previously obtained (60 mg, 0.2 mmol) in methanol solution with sodium metal (50 mg, 2.2 mmol) according to the conditions previously described. 20 The crude crystalline product obtained was purified by flash chromatography [silica gel; diethyl ether-carbon tetrachloride (1:1)] to give 48 mg of 7 (80%).
3r,4 -Dihydroxy-D-homo-17a-oxa-5r-androstan-17-one (8). The title dihydroxylactone 8 was obtained as a pure white crystalline solid in a 90-94% yield by oxidation of diol 5a (50 mg, 0.16 mmol) with magnesium monoperoxyphthalate (7-10 mol/mol of substrate), according to the reaction conditions described previously. 22 4-Hydroxy-D-homo-17a-oxaandrost-4-ene-3, 17-dione (9). Swern-type oxidation of the dihydroxylactone 8 (400 mg, 1.24 mmol) with DMSO (0.3 mL, 4.22 mmol) activated with trifluoroacetic anhydride (0.54 mL, 3.82 mmol), according to the reaction conditions previously described 22 yielded almost quantitatively a kinetic diosphenol, the 3-hydroxy-D-homo17a-oxa-5R-androst-2-ene-4,17-dione, 22 (387 mg, 98%) which, by further acid-catalyzed isomerization, was quantitatively (99%) converted in the title thermodynamic diosphenol 9.
3r-Hydroxy-17a-oxa-17a-homo-5r-androstane-4, 17-dione (10). To a solution of the dihydroxylactone 8 (100 mg, 0.31 mmol) in analar methylene chloride (2.0 mL), and 10 drops of methanol were added alumina [AlO 3, W200 acid activity super I (0% H2O), 335 mg] and oxone (250 mg, 0.41 mmol). The suspension was stirred at room temperature (18°C) until the steroid was consumed (6 h, TLC, ethyl acetate/n-hexane 5:1). After dilution with dried (MgSO4) methylene chloride, the suspension was filtered and the filtrate was washed with the same solvent (200 mL) and evaporated to dryness to give a crude white solid (97-99 mg, 97.6-99.6%), from which the pure title R-ketol-lactone 10 was isolated by crystallization.
4 -Cyano-3r,4 -dihydroxy-17a-oxa-17a-homo-5r-androstan-17-one (11). To 50 mg (0.156 mmol) of the R-ketollactone 10 were added acetone cyanohydrin (99.5 µL, 1.08 mmol) and triethylamine (7.75 µL), and the suspension was stirred at room temperature for 4 h until the reaction was complete (TLC). The reaction mixture was then poured into water (5-10 mL) with ice (5-10 g) and acetic acid (0.25-0.5 mL) under magnetic stirring. The precipitated product was filtered, washed with water followed by methylene chloride, and crystallized from ethyl acetate, giving the title cyanohydrin 11 as a white powder.
Biochemistry: Preparation of Placental Microsomes. Placental microsomes were obtained as described by Yoshida and Osawa 26 with some modifications. Human placentas obtained after delivery from a local hospital were placed in cold 67 mM potassium phosphate buffer (pH 7.4) containing 1% KCl. The cotyledon tissue was separated and homogenized in a Polytron homogenizer with 67 mM potassium phosphate buffer (pH 7.4) containing 0.25 M sucrose and 0.5 mM dithiothreitol (DTT, 1:1 w/v). The homogenate was centrifuged at 5000g for 30 min. The supernatant was centrifuged twice at 20000g for 30 min and at 148000g for 45 min to yield a microsomal pellet. The microsomes were washed and resuspended in 67 mM potassium phosphate buffer (pH 7.4) containing 0.25 M sucrose, 20% glycerol, and 0.5 mM DTT and stored at -80°C. All procedures were carried out at 0-5°C. Protein content was estimated by the Bradford method, 27 with bovine serum albumin (BSA) as standard. No significant enzyme activity loss occurred after 6 months.
Aromatase Assay Procedure. Aromatase activity was measured according to Thompson and Siiteri 23 and Heidrich et al. 28 Aromatase activity was evaluated by measuring the 3 H2O released from [1 -3 H]androstenedione during aromatization. All tested compounds were dissolved in ethanol and diluted in 67 mM potassium phosphate buffer (pH 7.4). Briefly, for the screening assay, 20 µg of protein of the microsomes, 40 nM [1 -3 H]androstenedione (1 µCi) purchased from PerkinElmer Life Sciences, and 2 µM each of the inhibitors were used, while for the IC50 determination, 200 nM (1 µCi) androstenedione and different concentrations of the inhibitors were used. The aromatase-catalyzed reaction was initiated by the addition of reduced nicotinamide adenine dinucleotide phosphate (NAD-PH, 150 µM), and incubations were performed in a shaking water bath at 37°C for 15 min. However, to minimize the timedependent loss of the initial aromatization rate, 10-30 nM [1 -3 H]androstenedione and 5 min incubation time were used for the kinetic studies. The reaction was terminated by addition of 500 µL of ice-cold distilled water and 1.5 mL of ice-cold chloroform. After centrifugation at 3200g for 10 min, the aqueous phase was added to 5% charcoal/0.5% dextran coated. After a new centrifugation cycle, the resulting supernatant was mixed with 1.5 mL of chloroform and centrifuged. The purified aqueous supernatant containing 3 H2O was mixed with a liquid scintillation cocktail (Universol) and counted in a Beckman liquid scintillation spectrometer (LS6500). All experiments were carried out in triplicate.
